dc.contributor.author | Tekgöz, Emre | |
dc.contributor.author | Çolak, Seda | |
dc.contributor.author | Yardımcı, Kübra G. | |
dc.contributor.author | Küçükşahin, Orhan | |
dc.contributor.author | Çınar, Muhammet | |
dc.contributor.author | Yılmaz, Sedat | |
dc.contributor.author | Kalyoncu, Umut | |
dc.contributor.author | Mercan, Rıdvan | |
dc.date.accessioned | 2022-05-11T14:05:03Z | |
dc.date.available | 2022-05-11T14:05:03Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1536-7355 | |
dc.identifier.uri | https://doi.org/10.1097/RHU.0000000000001699 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/4880 | |
dc.description.abstract | OBJECTIVE: Because of concerns about malignancy risks, using biological disease-modifying antirheumatic drugs (bDMARDs) in patients with a history of malignancy remains a challenging issue in rheumatology practice. This study aimed to investigate bDMARD preferences of physicians when treating of rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients with a history of malignancy. METHODS: The data for this cross-sectional study were gathered from the TReasure database using a date range of December 2017 and January 2020. Biological disease-modifying antirheumatic drug preferences were analyzed for 40 RA patients and 25 SpA patients with a history of malignancy. RESULTS: The most frequently prescribed bDMARD was rituximab, which was given to 28 RA patients (70%). For 25 patients (62.5%), the time between the diagnosis of malignancy and starting on a bDMARD regimen was less than 60 months, with a median interval of 43.5 months. Among SpA patients, the preferred bDMARDs were secukinumab and etanercept, which were each administered to 7 patients (28%). For 13 SpA patients (52%), the time between the diagnosis of malignancy and starting on bDMARDs was less than 60 months, with a median interval of 97 months. CONCLUSIONS: The observed bDMARD preferences may be related to the therapeutic effects of rituximab on lymphoproliferative malignancies, the protective effects of secukinumab on tumor progression, and the short half-life of etanercept. Biological disease-modifying antirheumatic drugs should be used in RA and SpA patients with malignancy in case of high inflammatory activity. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | NLM (Medline) | en_US |
dc.identifier.doi | 10.1097/RHU.0000000000001699 | |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | antirheumatic agent | en_US |
dc.subject | biological product | en_US |
dc.subject | cross-sectional study | en_US |
dc.subject | human | en_US |
dc.subject | neoplasm | en_US |
dc.subject | physician | en_US |
dc.subject | rheumatoid arthritis | en_US |
dc.subject | spondylarthritis | en_US |
dc.subject | Antirheumatic Agents | en_US |
dc.subject | Arthritis, Rheumatoid | en_US |
dc.subject | Biological Products | en_US |
dc.subject | Cross-Sectional Studies | en_US |
dc.subject | Humans | en_US |
dc.subject | Neoplasms | en_US |
dc.subject | Physicians | en_US |
dc.subject | Spondylarthritis | en_US |
dc.title | Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.identifier.volume | 28 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | e318 | en_US |
dc.identifier.endpage | e323 | en_US |
dc.institutionauthor | Mercan, Rıdvan | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 57202265979 | |
dc.authorscopusid | 57202958234 | |
dc.authorscopusid | 57211446536 | |
dc.authorscopusid | 14422446100 | |
dc.authorscopusid | 57397152100 | |
dc.authorscopusid | 57397904700 | |
dc.authorscopusid | 8392501600 | |
dc.identifier.wos | WOS:000759079900010 | en_US |
dc.identifier.scopus | 2-s2.0-85125018602 | en_US |
dc.identifier.pmid | 34014053 | en_US |